Research Papers

25 of 33 papers

CSV Excel
Quick filters: Open Data Open Code Pre-registered Funding Declared COI Declared Open Access Clear Filters
Should the two-trial paradigm still be the gold standard in drug assessment?
Zhan SJ; Kunz CU; Stallard N.
Pharm Stat (Unknown)
Published: 2022
4/6 Transparent
Code Funding Declared
CUSUMIN: A cumulative sum interval design for cancer phase I dose finding studies.
Hatayama T; Yasui S.
Pharm Stat (Unknown)
Published: 2022
2/6 Transparent
Study-design in pandemics: From surveillance and performance-evaluation to licensing and pharmacovigilance.
Bird SM.
Pharm Stat (Unknown)
Published: 2022
2/6 Transparent
Standard and reference-based conditional mean imputation.
Wolbers M; Noci A; Delmar P; Gower-Page C; Yiu S; Bartlett JW.
Pharm Stat (Unknown)
Published: 2022
4/6 Transparent
Code Funding Declared
Pairwise joint modeling of clustered and high-dimensional outcomes with covariate missingness in pediatric pneumonia ca…
Gachau S; Njagi EN; Molenberghs G; Owuor N; Sarguta R; English M; Ayieko P.
Pharm Stat (Unknown)
Published: 2022
3/6 Transparent
Funding Declared
Incorporating historical controls in clinical trials with longitudinal outcomes using the modified power prior.
Qi H; Rizopoulos D; Lesaffre E; van Rosmalen J.
Pharm Stat (Unknown)
Published: 2022
2/6 Transparent
Funding Declared
Decision rules for identifying combination therapies in open-entry, randomized controlled platform trials.
Meyer EL; Mesenbrink P; Dunger-Baldauf C; Glimm E; Li Y; König F; EU-PEARL (EU Patient-cEntric clinicAl tRial pLatforms) Consortium.
Pharm Stat (Unknown)
Published: 2022
4/6 Transparent
Code Funding Declared
Selection bias, investment decisions and treatment effect distributions.
Wiklund SJ; Burman CF.
Pharm Stat (Unknown)
Published: 2021
Treatment allocation strategies for umbrella trials in the presence of multiple biomarkers: A comparison of methods.
Ouma LO; Grayling MJ; Zheng H; Wason J.
Pharm Stat (Unknown)
Published: 2021
3/6 Transparent
Code Funding Declared
Potential impact of COVID-19 on ongoing clinical trials: a simulation study with the neurological Yale Global Tic Sever…
Lasch F; Guizzaro L; Aguirre Dávila L; Müller-Vahl K; Koch A.
Pharm Stat (Unknown)
Published: 2021
3/6 Transparent
Data Funding Declared
A novel equivalence probability weighted power prior for using historical control data in an adaptive clinical trial de…
Bennett M; White S; Best N; Mander A.
Pharm Stat (Unknown)
Published: 2021
4/6 Transparent
Data Funding Declared
A confidence function-based posterior probability design for phase II cancer trials.
Shan M.
Pharm Stat (Unknown)
Published: 2020
1/6 Transparent
A stochastically curtailed two-arm randomised phase II trial design for binary outcomes.
Law M; Grayling MJ; Mander AP.
Pharm Stat (Unknown)
Published: 2020
4/6 Transparent
Data Code Funding Declared
Controlling type I error rates in multi-arm clinical trials: A case for the false discovery rate.
Wason JMS; Robertson DS.
Pharm Stat (Unknown)
Published: 2020
1/6 Transparent
Funding Declared
Imputation of missing covariate in randomized controlled trials with a continuous outcome: Scoping review and new resul…
Kayembe MT; Jolani S; Tan FES; van Breukelen GJP.
Pharm Stat (Unknown)
Published: 2020
A critical review of graphics for subgroup analyses in clinical trials.
Ballarini NM; Chiu YD; König F; Posch M; Jaki T.
Pharm Stat (Unknown)
Published: 2020
1/6 Transparent
Funding Declared
Reference-based sensitivity analysis for time-to-event data.
Atkinson A; Kenward MG; Clayton T; Carpenter JR.
Pharm Stat (Unknown)
Published: 2019
1/6 Transparent
Funding Declared
Empirical evaluation of the implementation of the EMA guideline on missing data in confirmatory clinical trials: Specif…
Häckl S; Koch A; Lasch F.
Pharm Stat (Unknown)
Published: 2019
2/6 Transparent
Data Funding Declared
Design of experiments and the virtual PCR simulator: An online game for pharmaceutical scientists and biotechnologists.
Fellermann H; Shirt-Ediss B; Kozyra J; Linsley M; Lendrem D; Isaacs J; Howard T.
Pharm Stat (Unknown)
Published: 2019
1/6 Transparent
Funding Declared
Blinded continuous monitoring in clinical trials with recurrent event endpoints.
Friede T; Häring DA; Schmidli H.
Pharm Stat (Unknown)
Published: 2018
1/6 Transparent
A practical guide to pre-trial simulations for Bayesian adaptive trials using SAS and BUGS.
Hansen CH; Warner P; Walker A; Parker RA; Whitaker L; Critchley HOD; Weir CJ.
Pharm Stat (Unknown)
Published: 2018
3/6 Transparent
Data Funding Declared
A proposal for a new PhD level curriculum on quantitative methods for drug development.
Jaki T; Gordon A; Forster P; Bijnens L; Bornkamp B; Brannath W; Fontana R; Gasparini M; Hampson LV; Jacobs T; Jones B; Paoletti X; Posch M; Titman A; Vonk R; Koenig F.
Pharm Stat (Unknown)
Published: 2018
1/6 Transparent
Funding Declared
How to use prior knowledge and still give new data a chance?
Weber K; Hemmings R; Koch A.
Pharm Stat (Unknown)
Published: 2018
1/6 Transparent
Funding Declared
Response-adaptive designs for binary responses: How to offer patient benefit while being robust to time trends?
Villar SS; Bowden J; Wason J.
Pharm Stat (Unknown)
Published: 2017
1/6 Transparent
Funding Declared
Misspecification of at-risk periods and distributional assumptions in estimating COPD exacerbation rates: The resultant…
Law M; Sweeting MJ; Donaldson GC; Wedzicha JA.
Pharm Stat (Unknown)
Published: 2016
2/6 Transparent
Data Funding Declared